Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026
Abivax announced seven accepted abstracts on obefazimod, including four oral presentations, at UEG Week 2026 in Barcelona, October 17-20. The data span the Phase 3 ABTECT Maintenance and Induction trials in ulcerative colitis, 3-year interim Phase 2 follow-up after dose de-escalation to 25 mg, and preclinical anti-fibrotic and anti-tumor findings.
Key figures
- Drug Name
- obefazimod (ABX464)
- Phase Of Trial
- Phase 3
- Conference
- UEG Week 2026, Barcelona, October 17-20, 2026
- Accepted abstracts
- 7
- Oral presentations
- 4
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.